Current Report Filing (8-k)
May 05 2022 - 04:07PM
Edgar (US Regulatory)
0001213037FALSE00012130372022-05-052022-05-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 5, 2022
Cardiff Oncology, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|
|
|
Delaware |
001-35558
|
27-2004382 |
|
(State or other jurisdiction |
(Commission
File Number)
|
IRS Employer |
|
of incorporation or organization) |
|
Identification No.) |
11055 Flintkote Avenue
San Diego, CA 92121
(Address of principal executive offices)
Registrant’s telephone number, including area code:
(858) 952-7570
(Former name or former address, if changed since last
report)
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Title of each class:
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered:
|
|
Common Stock
|
|
CRDF
|
|
Nasdaq Capital Market |
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
o
Written communication pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o
Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Indicate by check mark whether the registrant is an emerging
growth company as defined in as defined in Rule 405 of the
Securities Act of 1933 (§230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2
of this chapter). Emerging growth
company o
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the
Exchange Act. o
Item 2.02
Results of Operations and Financial Conditions.
On May 5, 2022, Cardiff Oncology, Inc. issued a press release
announcing company highlights and financial results for the third
quarter ended March 31, 2022. A copy of the press release is
furnished as Exhibit 99.1 to this Form 8-K.
The information disclosed under this Item 2.02, including Exhibit
99.1 hereto, is being furnished and shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended, nor shall it be incorporated by reference into any
registration statement or other document pursuant to the Securities
Act of 1933, as amended, except as expressly set forth in such
filing.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly
authorized.
Dated:
May 5, 2022
|
|
|
|
|
|
|
|
|
|
CARDIFF ONCOLOGY, INC. |
|
|
|
|
|
By: |
/s/ Mark Erlander |
|
|
Mark Erlander |
|
|
Chief Executive Officer |
Cardiff Oncology (NASDAQ:CRDF)
Historical Stock Chart
From May 2022 to Jun 2022
Cardiff Oncology (NASDAQ:CRDF)
Historical Stock Chart
From Jun 2021 to Jun 2022
